Indian Pharma Market
Indian pharma market for anti-malarial products has shown declining trend over the last five years. Ipca, a leading player in anti-malarial products in India has also seen a downtrend in sales of these drugs. However, the trend in de-growth has been sharper in the industry when compared with a decline in IPCA’s revenue from anti-malaria products.
[Image 1: Compare screen shows anti-malarial products sales for the industry and IPCA]
[Image 2: Compare screen shows index for anti-malarial products sales for the industry and IPCA]
IPCA derives over 16% of revenues from anti-malaria products (Image 3). The company has maintained its position as a market leader in the domestic market for anti-malarial products with the share of ~50%. However, in recent months, IPCA’s market share has started dwindling marginally (Image 4).
Anti-malarial products account for 0.44% of the Indian pharma market while the average market share of the companies in this segment is pegged at 0.67%, which is fairly constant.
[Image 3: Therapeutic revenue contribution for IPCA]
[Image 4: Therapeutic market share for IPCA]
FiND collects, organizes and performs deep-dive analytics on structured and unstructured data sets to provide unique insights into companies, industries, and countries. Some of the key data sets that we offer for Pharmaceutical sector are litigation, new drug opportunity, detailed drug profile and clinical trial data from multiple locations.
To know more about FiND, email us at email@example.com
The Indian pharma market has grown at an 8% compounded annual growth rate (CAGR) during the calendar year 2013-2017, helped by impressive growth in chronic segment sales. The pharma sales stood at USD 17.87 billion for the moving annual total (MAT) ended December 2017, up from USD 13.35 billion in CY13 (Image 1). On a year-on-year basis, the pharma market witnessed an 8.83% increase in sales for twelve months ended December 2017.
[Image 1: The Indian pharma market sales – moving annual total]
The chronic segment (a disease that persists over a long period of time such as diabetes, high blood pressure, Alzheimer etc.), which accounts for 32% of total Indian pharma market, staged a stellar performance during the CY13-17 period. Changes in lifestyle and food habits coupled with higher disposable income fueled growth in chronic diseases in recent years. Read the rest of this entry »